Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGA4 | P13612 | 18/20 | 0.43 |
| ▸ | ITGB1 | P05556 | 17/20 | 0.43 |
| ▸ | ITGB7 | P26010 | 14/20 | 0.43 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.31 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.31 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.30 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21977922 | 1.00 | ITGA4 (0.43) | ITGA4ITGB1ITGB7HCRTR1HCRTR2 | |
| SCHEMBL21977919 | 1.00 | ITGA4 (0.43) | ITGA4ITGB1ITGB7HCRTR1HCRTR2 | |
| SCHEMBL21977701 | 0.91 | ITGA4 (0.43) | ITGA4ITGB1ITGB7 | |
| SCHEMBL21977700 | 0.91 | ITGA4 (0.43) | ITGA4ITGB1ITGB7 | |
| SCHEMBL21977766 | 0.90 | ITGA4 (0.43) | ITGA4ITGB1ITGB7HCRTR2 | |
| SCHEMBL21977764 | 0.90 | ITGA4 (0.43) | ITGA4ITGB1ITGB7HCRTR2 | |
| SCHEMBL23778768 | 0.83 | ITGB1 (0.34) | ITGA4ITGB1ITGB7 | |
| SCHEMBL21977635 | 0.83 | ITGB1 (0.34) | ITGA4ITGB1ITGB7 | |
| SCHEMBL21977632 | 0.83 | ITGB1 (0.34) | ITGA4ITGB1ITGB7 | |
| SCHEMBL22037325 | 0.83 | ITGA4 (0.37) | ITGA4ITGB1S1PR1S1PR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3873900-B1 | IMIDAZO[1,2-A]PYRIDINE DERIVATIVES AS ALPHA4BETA7 INTEGRIN INHIBITORS FOR THE TREATMENT OF INFLAMMATORY DISEASES | GILEAD SCIENCES INC (US) | 2025-01-08 | — | — | EP | disclosed |
| US-20220135561-A1 | IMIDAZOPYRIDINE DERIVATIVES | GILEAD SCIENCES, INC. | 2022-05-05 | — | — | US | disclosed |
| US-20220135561-A1 | IMIDAZOPYRIDINE DERIVATIVES | GILEAD SCIENCES, INC. | 2022-05-05 | — | — | US | disclosed |
| US-11174256-B2 | Imidazopyridine derivatives | GILEAD SCIENCES, INC. (US) | 2021-11-16 | — | — | US | disclosed |
| US-11174256-B2 | Imidazopyridine derivatives | GILEAD SCIENCES, INC. (US) | 2021-11-16 | — | — | US | disclosed |
| US-20200165248-A1 | IMIDAZOPYRIDINE DERIVATIVES | GILEAD SCIENCES, INC. | 2020-05-28 | — | — | US | disclosed |
| US-20200165248-A1 | IMIDAZOPYRIDINE DERIVATIVES | GILEAD SCIENCES, INC. | 2020-05-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11174256-B2 | Imidazopyridine derivatives | TPMT, IRAK4, CFTR | ITGA4 960/4885ITGB1 1459/4885ITGB7 1490/4885 |
| US-20220135561-A1 | IMIDAZOPYRIDINE DERIVATIVES | TPMT, IRAK4, CFTR | ITGA4 960/4885ITGB1 1459/4885ITGB7 1490/4885 |
| US-20200165248-A1 | IMIDAZOPYRIDINE DERIVATIVES | TPMT, IRAK4, CFTR | ITGA4 960/4885ITGB1 1459/4885ITGB7 1490/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.